AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Corbus Pharmaceuticals Announces CEO to Participate in Piper Sandler Virtual Oncology Symposium.
ByAinvest
Tuesday, Oct 7, 2025 8:31 am ET1min read
Corbus Pharmaceuticals Holdings, Inc. announced that CEO Yuval Cohen will participate in a Fireside Chat at the Piper Sandler Virtual Oncology Symposium on October 9, 2025. Corbus is a clinical stage oncology and obesity company with a pipeline including CRB-701 and CRB-601. The company is committed to bringing innovative approaches to well-understood biological pathways to help people defeat serious illness.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has announced that Yuval Cohen, Ph.D., the company's Chief Executive Officer, will participate in a Fireside Chat at the Piper Sandler Virtual Oncology Symposium on October 9, 2025. The event, hosted by Biren Amin, Managing Director of Piper Sandler - Healthcare Equity Research, will take place from 10:00 AM ET [1].Corbus Pharmaceuticals is a clinical stage oncology and obesity company dedicated to bringing innovative scientific approaches to well-understood biological pathways. The company's pipeline includes CRB-701, a next-generation antibody drug conjugate targeting the expression of Nectin-4 on cancer cells, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells [1].
The company recently received FDA fast track designation for CRB-701 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma previously treated with platinum-based chemotherapy and an anti-PD-(L)1 therapy. This designation highlights Corbus's commitment to advancing innovative treatments for serious illnesses [2].
Corbus Pharmaceuticals is headquartered in Norwood, Massachusetts, and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn, and Facebook.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet